 |
Asian Activities Report for October 10, 2011: Carabella Resources (ASX:CLR) Appoints New Managing Director to Strengthen Expertise in the Coal Industry
OCT 10, 2011 12:00 - Article Views: 1,480
Asian Activities Report for October 10, 2011 includes: Carabella Resources Limited (ASX:CLR) announced the appointment of experienced coal industry executive Anthony Quin as Managing Director; Tasman Resources Limited (ASX:TAS) has signed a conditional agreement with Rio Tinto Limited (ASX:RIO) for the funding of an accelerated exploration program on Tasman's Vulcan prospect; Acer Energy Limited (ASX:ACN) has executed a conditional Sale and Purchase Agreement with Sundance Energy Australia Limited (ASX:SEA) to acquire all of Sundance's 23.33% working interest in Petroleum Exploration Licence 100; Starpharma Holdings Limited (ASX:SPL) has received agreement from the US Food and Drug Administration regarding the Phase 3 clinical trial program for the Company's VivaGel (R) bacterial vaginosis treatment. |
 |
 |
Starpharma Holdings Limited's (ASX:SPL) Deal With Elanco Triggers a Share Purchase Plan Extension
MAY 11, 2009 11:44 - Article Views: 2,278
The Board of Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) has decided to further extend the closing date of the share purchase plan (SPP) due to the Elanco Agreement announcement made today. |
|
 |
Starpharma Holdings Limited (ASX:SPL) and Elanco Sign A Collaborative Research, License And Commercialisation Agreement
MAY 11, 2009 10:32 - Article Views: 1,715
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the signing of a collaborative research, license and commercialisation agreement with Elanco, the animal health division of US pharmaceutical company Eli Lilly and Company (NYSE:LLY). |
|
 |
Starpharma Holdings Limited (ASX:SPL) Raises Additional Capital Up To A$4.6 Million Via Institutional Placement
APR 7, 2009 09:42 - Article Views: 2,508
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced a successful capital raising of at least A$4.3 million and up to A$4.6 million, through a private placement to existing and new institutional and sophisticated investors. |
|
 |
Starpharma Holdings Limited (ASX:SPL) Completes Patient Testing In Retention Of VivaGel Antiviral Activity Study
MAR 19, 2009 12:51 - Article Views: 2,329
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) today announced the completion of patient testing in a clinical trial of VivaGel(R) that explores the length of time the antiviral activity of VivaGel remains following application. |
|
 |
Starpharma Holdings Limited (ASX:SPL) Announces Its Financial Results For The 6 Months Ending 31 December 2008
FEB 19, 2009 17:18 - Article Views: 2,051
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) Net loss after tax was A$1.9 million, with operating cash outflows of A$2.5 million for the half year, 12% less than the same period in the prior year. Cash at 31 December was A$6.1 million. Total revenue and other income was A$5.1 million for the half year with revenue from continuing operations A$1.0 million for the six months, up 6% compared with the same period in the prior year. |
|
|
Starpharma Holdings Limited (ASX:SPL) Topical Microbicide Field Receives a Boost with Human Efficacy Result
FEB 10, 2009 13:47 - Article Views: 1,730
Starpharma Holdings Limited (ASX:SPL)(PINK:SPHRY) welcomes news that PRO2000 gel, a candidate microbicide similar to Starpharma's own VivaGel(R), has demonstrated partial effectiveness in preventing HIV infection in women. The study also found that 99% of women in the trial reported that they would use a topical microbicide gel that was approved for HIV prevention. |
|
|
Starpharma Holdings Ltd (ASX:SPL) Quarterly Activities Report to Dec 31, 2008
FEB 3, 2009 13:40 - Article Views: 989
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) Quarterly Activities Report to Dec 31, 2008 |
|
|
Starpharma Holdings Ltd (ASX:SPL) Dendrimer Reduces Toxicity of Cancer Drug
DEC 17, 2008 13:19 - Article Views: 1,593
Starpharma Holdings Ltd (ASX:SPL)(PINK:SPHRY) today reported an important advance in its dendrimer-based drug-delivery program.
|
|
